![](data:image/svg+xml;charset=utf-8,<svg height="32" width="135" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
₹ 700.30
Open
691.8High
704.9Low
685.85Prev Close
698.95P/E
55.13Median P/E
44.08P/B
6.58Median P/B
3.83Market Cap
281.03BPEG
4.24Div.Yield
0.07Bid
-Ask
-Large Cap
281.03B Mkt. Cap.Volatility
-Beta
0.99Genie Says
Influencer Count
-| Days | BSE | NSE |
|---|
| 5 | 706.04 | 706.53 |
| 10 | 719.28 | 719.75 |
| 20 | 715.07 | 715.57 |
| 50 | 716.48 | 716.77 |
| 100 | 716.43 | 716.66 |
| 300 | 743.57 | 743.76 |
BSE
539268NSE
SYNGENEISIN
INE398R01022Syngene International Limited is an integrated research, development, and manufacturing services company. The Company is engaged in providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies worldwide. Its services include drug discovery and development capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process research and development, current good manufacturing practice (cGMP) manufacturing, formulation, and analytical development, along with clinical development services. It offers SynVent, a therapeutic discovery and development platform for executing drug discovery projects. SynVent's portfolio covers modalities and therapeutic areas ranging from small molecule inhibitors to targeted protein stabilization. It serves the pharmaceutical, biotechnology, and specialty chemical sectors, among others. It operates multi-modal biologics manufacturing facility.
Jonathan Hunt
Chief Executive Officer, Managing Director, Executive DirectorSibaji Biswas
Chief Financial Officer, Executive DirectorAndrew Webster
Chief Human Resource OfficerKenneth Barr
Senior Vice President - Discovery ServicesAlex Del Priore
Senior Vice President - Manufacturing ServicesPriyadarshini Mahapatra
Compliance Officer, Company SecretaryCaroline Hempstead
Head of Corporate AffairsAlok Mehrotra
Chief Quality Officer